Streetwise Regenerative Medicine Articles



Biopharma Co. Ceases Program to Optimize Resources
Source: Hartaj Singh  (5/16/23)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. More >


Co.'s New Cell Therapy Shows Positive Effects
Source: Emily Bodnar  (4/19/23)
Disease response and survival rates are impressive in updated results from several studies, noted an H.C. Wainwright & Co. report. More >


Follow-up Results From T2 Diabetes Trial Positive
Source: Dr. Jonathan Aschoff   (4/14/23)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. More >


Biotech Improves Efficiency of Its New Immunotherapy
Source: Dr. Jonathan Aschoff  (3/22/23)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report. More >


Data on New Cell Therapy for LBCL Encouraging, Analyst Says
Source: Justin Zelin   (12/16/22)
The biopharma behind the investigational treatment plans to advance it into a potentially pivotal clinical program next year, noted a BTIG report. More >


HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422
Source: Yun Zhong  (8/15/22)
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics. More >


Biopharma Co. Planning BLA for DMD Drug
Source: Yun Zhong, Ph.D.  (8/5/22)
Sarepta Therapeutics Inc. recently announced that it intends to submit a BLA to the U.S. FDA for its SRP-9001, a gene therapy to treat Duchenne muscular dystrophy. Equity research firm BTIG LLC advised in a research update that SRP-9001 seems to have met the necessary criteria for receiving accelerated approval and it expects an AdCom will be established shortly. BTIG stated that it rates Sarepta Therapeutics as a "Buy" and has a $125 price target for the company's shares. More >


Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports  (7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system. More >


Small Biomedical Device Co. Is Ready to Take a Big Step Into Success
Source: Tim Weintraut  (6/8/22)
After weathering some major setbacks, PetVivo Holdings Inc. is stepping it up. With their new product for osteoarthritis and the team's perseverance, they may soon show themselves as a diamond in the rough. More >


Biopharma Co. Posts Positive Data in Ph. 1 Cancer Trials
Source: Streetwise Reports  (4/25/22)
Nkarta Inc. shares traded over 120% higher after the company reported positive dosing data from two separate Phase 1 clinical trials evaluating the use of natural killer cell therapies to target r/r acute myeloid leukemia and myelodysplastic syndrome and r/r B cell malignancies. More >


FDA Grants RMAT Status for T-Cell Therapy for Six Viruses
Source: Streetwise Reports  (4/20/22)
Shares of AlloVir Inc. traded 18% higher after the firm reported that the U.S. FDA awarded Regenerative Medicine Advanced Therapy designation to its posoleucel for use in preventing life-threatening infections from six viruses in allogeneic hematopoietic cell transplant patients. More >


Regenerative Medicine Co. Posts 38% Sales Gain in 2021
  (3/2/22)
Organogenesis Holdings Inc. shares traded 23% higher after the company reported FY/21 financial results that included a 46% YoY increase in revenue from its Advanced Wound Care products sales. More >


Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment
Source: Streetwise Reports  (11/20/21)
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome. More >


Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases
Source: Streetwise Reports  (7/2/21)
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. More >


Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial
Source: Streetwise Reports  (6/28/21)
Intellia Therapeutics soared to a new 52-week high after the firm reported that in a Phase 1 clinical study with partner Regeneron, it had achieved "landmark clinical data" that demonstrated deep reduction in disease-causing protein after a single infusion of NTLA-2001, an investigational CRISPR therapy for transthyretin (ATTR) amyloidosis.


More >


Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >


CryoLife Shares Trade 18% Higher on Q1 Financial Results
Source: Streetwise Reports  (4/30/21)
Shares of CryoLife Inc. set a new 52-week high intraday price after the company reported that total revenues in Q1/21 increased by 7% YoY to $71.1 million. More >


Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results
Source: Streetwise Reports  (2/17/21)
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report. More >


Analyst: Differences Between Two Possible COVID-19 Therapies Noteworthy
Source: Streetwise Reports  (12/23/20)
The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report. More >


Organogenesis Shares Rise 20% on Q3 Net Revenue Growth and FY Guidance
Source: Streetwise Reports  (10/15/20)
Shares of Organogenesis Holdings traded higher after the company reported preliminary Q3/20 financial results demonstrating a 55% increase in year-over-year revenue. More >


Phase 3 COVID-19 Study of Firm's Stem Cell Product Exceeds 50% Enrollment
Source: Streetwise Reports  (10/14/20)
The study design and goals and Mesoblast's next steps are reviewed in a Dawson James Securities report. More >


Regenerative Medicine Firm Reports Early Results from COVID-19 Trials
Source: Streetwise Reports  (6/17/20)
Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. More >


Mesoblast Shares Soar 120% After Reporting 83% Survival Rate in COVID-19 Patients with ARDS
Source: Streetwise Reports  (4/24/20)
Shares of Mesoblast more than doubled and set a new 52-week high price after the company reported that it achieved a 83% survival rate in New York ventilator-dependent COVID-19 patients with moderate to severe acute respiratory distress syndrome who were treated with its allogeneic cell therapy remestemcel-L. More >


Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress
Source: Streetwise Reports  (4/15/20)
A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. More >


Three COVID-19 Patients Treated with PLX Cells
Source: Streetwise Reports  (4/1/20)
Two programs, one new and the other ongoing, involving Pluristem Therapeutics' regenerative products are reviewed in a Dawson James report. More >


Showing Results: 1 to 25 of 177 Next

Notable Quotes

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts